Bullish On Cidara Therapeutics As It Doubles Down On CD388 For Universal Flu Prevention

Company Overview - Cidara Therapeutics is a small biotech company focused on developing drug-Fc conjugates (DFCs) for influenza prevention [1] - The company utilizes a proprietary platform named Cloudbreak to develop its main product, CD388 [1] Product Development - CD388 is positioned as the primary product in Cidara's pipeline, indicating a strategic focus on innovative therapeutic solutions for influenza [1]